Authors
Latest:
Dr. Waxman on the Future of Treatment in Multiple MyelomaAdam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.
Latest:
Dr. Brufsky on the Utility of Zanidatamab in HER2+ Breast CancerAdam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.
Latest:
Audience Q&A: Future Directions in Breast Cancer CareClosing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.
Latest:
Dr. Dicker on DNA Sequencing for Prostate CancerAdam P. Dicker, MD, PhD, professor, chair, Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses DNA sequencing for patients with prostate cancer.
Latest:
Dr. Kibel on Take-Home Messages in Field of Genitourinary CancersAdam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.
Latest:
Dr. Feldman on Men With Prostate Cancer Receiving Treatment After Active SurveillanceAdam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.
Latest:
Dr. Kardosh Discusses Epacadostat in Gastric/GEJ AdenocarcinomaAdel Kardosh, MD, postdoctoral medical fellow, oncology, Stanford Medicine, discusses epacadostat in gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Latest:
Dr. Hormigo on the Current Treatment Landscape of GlioblastomaAdilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.
Latest:
Dr. Aditi Kumar on Aggressive Multimodal Therapy in Anaplastic Thyroid CancerAditi Kumar, MD, endocrinology fellow at the University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer. A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.
Latest:
Dr. Bardia on the Need to Develop Additional Therapies in Metastatic TNBCAditya Bardia, MD, MPH, discusses the need to develop additional therapies for patients with metastatic triple-negative breast cancer.
Latest:
Treatment Advances in HR+ Advanced Breast CancerAditya Bardia, MD, MPH, discusses the current standard of care for HR+ advanced breast cancer and reacts to treatment advances with the availability of CDK4/6 inhibitors.
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate CancerDespite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Latest:
Keeping Ahead of Oncology Advances Requires VigilanceAditya V. Shreenivas, MD, MSCR, says a habit of continuous learning is the ideal way to stay informed about the latest data.
Latest:
Dr. Suarez Mora On Sequential Sampling of IP Fluid During ChemotherapyAdria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.
